
CANNAPHARMARX, INC.
72
Recent news coverage highlights broader market pressures affecting technology and infrastructure sectors, which may indirectly influence CANNAPHARMARX, INC.'s operating environment.
- Stocks have been pressured by weakness in chipmakers and AI-infrastructure stocks, reflecting volatility in related markets [N1].
- Electric vehicle companies, including Tesla, have initiated a massive recall in China, indicating supply chain and regulatory challenges in the sector [N2].
- A rout in chipmakers has weighed on the broader market, contributing to overall market uncertainty [N3].
CANNAPHARMARX, INC. is a publicly reporting company with recent SEC filings providing financial data through Q3 2026. The company reported modest revenues and positive net income for the latest quarter. However, liquidity ratios indicate current liabilities substantially exceed current assets, suggesting potential short-term financial challenges. The company is categorized as a smaller reporting company and does not provide detailed risk disclosures in its latest filings. Publicly available information does not specify the company's sector, industry, or geographic focus.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. CANNAPHARMARX, INC. reported revenues of $137,705 and net income of $645,416 for the quarter ending September 30, 2026, with liquidity ratios indicating significant current liabilities relative to current assets [S2].
The company reported positive net income in the latest quarter despite low revenues, which may indicate operational efficiency or non-operating income sources. The presence of recent SEC filings suggests ongoing compliance and transparency. Market conditions reflected in recent news show volatility in technology and infrastructure sectors, which may indirectly impact the company depending on its business focus.
Liquidity ratios reveal a current ratio of 0.05 and cash ratio of 0.01 as of September 30, 2026, indicating that current liabilities significantly exceed current assets, which could pose short-term financial risks. The absence of detailed risk disclosures and sector information limits clarity on business risks. The company's very low market price and lack of market capitalization data suggest limited market interest or liquidity.
There is insufficient public information to assess CANNAPHARMARX, INC.'s competitive advantages or moat. The lack of disclosed sector and industry details limits visibility into its market positioning or barriers to entry.
• Liquidity Risk: The company's current liabilities far exceed current assets, with a current ratio of 0.05 and cash ratio of 0.01 as of 2026-09-30, indicating potential difficulties in meeting short-term obligations [S2].
• Information Transparency: As a smaller reporting company, CANNAPHARMARX, INC. is not required to provide detailed risk factor disclosures, limiting visibility into potential operational or market risks [S2].
• Market and Sector Uncertainty: The lack of disclosed sector and industry information restricts understanding of the company's competitive environment and exposure to sector-specific risks.
Business trends: The company reports modest revenues and positive net income amid a volatile market environment affecting technology and infrastructure sectors.
Execution milestones: Continued SEC compliance with quarterly filings provides transparency; monitoring liquidity management is critical.
Key risks: Significant liquidity constraints and limited public information on business operations and sector exposure pose challenges to assessing stability and growth potential.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- CANNAPHARMARX, INC. is a publicly reporting company with recent SEC filings including a 10-K filed on 2026-03-31 and a 10-Q filed on 2026-11-17 [S1][S2].
- As of the quarter ending 2026-09-30, the company reported revenues of $137,705 and net income of $645,416 [S2].
- The company reported cash and cash equivalents of $633 as of 2026-03-31 and current assets of $1,740,152 as of 2026-09-30 [S2].
- Current liabilities as of 2026-09-30 were $32,669,280, resulting in a current ratio of 0.05 and a cash ratio of 0.01, indicating liquidity constraints [S2].
- Earnings per share basic and diluted were reported as $0 for the period ending 2026-09-30 [S2].
- The company is classified as a smaller reporting company and is not required to provide detailed risk factor disclosures in its latest filings [S2].
- Recent business news relevant to the company’s market environment includes pressure on stocks from weakness in chipmakers and AI infrastructure stocks, and a massive recall by electric vehicle companies in China, reflecting broader market volatility [N1][N2][N3].
Generated 2026-11-17
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-17 | 10-Q
- N1 | 2026-08-24 | www.nasdaq.com | Stocks Pressured by Weakness in Chipmakers and AI-Infrastructure Stocks | https://www.nasdaq.com/articles/stocks-pressured-weakness-chipmakers-and-ai-infrastructure-stocks
- N2 | 2026-08-24 | www.nasdaq.com | Tesla and Other Electric Vehicle Companies Begin Massive China Recall | https://www.nasdaq.com/articles/tesla-and-other-electric-vehicle-companies-begin-massive-china-recall
- N3 | 2026-08-24 | www.nasdaq.com | Rout in Chipmakers Weighs on Broader Market | https://www.nasdaq.com/articles/rout-chipmakers-weighs-broader-market
- N4 | 2026-08-18 | www.nasdaq.com | Intrusion (INTZ) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/intrusion-intz-q2-2026-earnings-call-transcript
- N5 | 2026-08-18 | www.nasdaq.com | US Antimony (UAMY) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/us-antimony-uamy-q2-2026-earnings-call-transcript
- N6 | 2026-08-18 | www.nasdaq.com | Anterix (ATEX) Q1 2027 Earnings Call Transcript | https://www.nasdaq.com/articles/anterix-atex-q1-2027-earnings-call-transcript
- N7 | 2026-08-18 | www.nasdaq.com | Broadcom vs. Nvidia: 1 Metric Shows Which Artificial Intelligence (AI) Chipmaker Is the Better Bargain | https://www.nasdaq.com/articles/broadcom-vs-nvidia-1-metric-shows-which-artificial-intelligence-ai-chipmaker-better
- N8 | 2026-08-18 | www.nasdaq.com | Mineralys (MLYS) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/mineralys-mlys-q2-2026-earnings-call-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


